<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6751">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987727</url>
  </required_header>
  <id_info>
    <org_study_id>MAF-AGN-OPH-DE-011</org_study_id>
    <nct_id>NCT00987727</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye</brief_title>
  <official_title>Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity
      in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Global Ocular Staining Score at Day 35</measure>
    <time_frame>Baseline, Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35</measure>
    <time_frame>Baseline, Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sodium hyaluronate 0.18% (VISMED® Multi)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)</intervention_name>
    <description>One drop in each eye three to six times daily, as needed</description>
    <arm_group_label>1</arm_group_label>
    <other_name>OPTIVE® MD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium hyaluronate 0.18% (VISMED® Multi)</intervention_name>
    <description>One drop in each eye three to six times daily, as needed</description>
    <arm_group_label>2</arm_group_label>
    <other_name>VISMED® Multi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been using artificial tears for at least 3 months prior to study inclusion

          -  Have been using preservative free artificial tears at least three times daily (TIB)
             for at least 2 weeks immediately prior to study inclusion

          -  Having moderate to severe symptoms suggestive of dry eye

        Exclusion Criteria:

          -  Current enrollment in an investigational drug or device study or participation in
             such a study within 3 months prior to entry into this study

          -  Moderate to severe blepharitis

          -  History or active signs of ocular trauma, ocular infection, or ocular inflammation
             within the last 3 months

          -  History or active signs of ocular allergic disease or ocular herpes within the last
             year

          -  History or active signs of severe or serious ocular conditions such as inflammatory
             corneal ulcers, recurrent erosions, and uveitis at any time.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 17, 2011</lastchanged_date>
  <firstreceived_date>September 29, 2009</firstreceived_date>
  <firstreceived_results_date>August 17, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Vice President Medical Affairs</name_title>
    <organization>Allergan, Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)</title>
          <description>carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)</description>
        </group>
        <group group_id="P2">
          <title>Sodium Hyaluronate 0.18% (VISMED® Multi)</title>
          <description>sodium hyaluronate 0.18% (VISMED® Multi)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)</title>
          <description>carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)</description>
        </group>
        <group group_id="B2">
          <title>Sodium Hyaluronate 0.18% (VISMED® Multi)</title>
          <description>sodium hyaluronate 0.18% (VISMED® Multi)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Global Ocular Staining Score at Day 35</title>
        <description>Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).</description>
        <time_frame>Baseline, Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: All subjects who were randomised, who received at least one dose of the study product, had at least one follow-up visit and who did not have significant protocol violations and who completed the assessment of this outcome measure at Day 35.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)</title>
            <description>carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)</description>
          </group>
          <group group_id="O2">
            <title>Sodium Hyaluronate 0.18% (VISMED® Multi)</title>
            <description>sodium hyaluronate 0.18% (VISMED® Multi)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Global Ocular Staining Score at Day 35</title>
            <description>Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).</description>
            <units>Number on a scale (score)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" spread="1.59"/>
                  <measurement group_id="O2" value="5.9" spread="1.47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.8" spread="1.95"/>
                  <measurement group_id="O2" value="-1.8" spread="2.30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35</title>
        <description>Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.</description>
        <time_frame>Baseline, Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: All subjects who were randomised, who received at least one dose of the study product, had at least one follow-up visit and who did not have significant protocol violations and who completed the assessment of this outcome measure at Day 35.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)</title>
            <description>carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)</description>
          </group>
          <group group_id="O2">
            <title>Sodium Hyaluronate 0.18% (VISMED® Multi)</title>
            <description>sodium hyaluronate 0.18% (VISMED® Multi)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35</title>
            <description>Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.</description>
            <units>Number on a scale (score)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49.05" spread="17.060"/>
                  <measurement group_id="O2" value="51.98" spread="18.164"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.58" spread="19.047"/>
                  <measurement group_id="O2" value="-13.66" spread="16.542"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population included all subjects who were randomized and treated with at least one dose of the study product. (Note: 3 randomized subjects in the VISMED® Multi group did not receive a dose and were not included in the safety population).</desc>
      <group_list>
        <group group_id="E1">
          <title>Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)</title>
          <description>carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)</description>
        </group>
        <group group_id="E2">
          <title>Sodium Hyaluronate 0.18% (VISMED® Multi)</title>
          <description>sodium hyaluronate 0.18% (VISMED® Multi)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic Lateral Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
